 |
|
|
| |
High Efficacy and Favourable Safety of ABT-493 + ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients With Cirrhosis (SURVEYOR-I)
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Ed Gane1, Fred Poordad2, Armen Asatryan3, Jacob Lalezari4, Tarek Hassanein5, Humberto Aguilar6, Teresa I Ng3, Ran Liu3, Chih-Wei Lin3, Jens Kort3, Federico J Mensa3
1Auckland Clinical Studies, Auckland, New Zealand; 2Texas Liver Insti tute, San Antonio, Texas, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Quest Clinical Research, San Francisco, California, United States; 5Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States; 6Louisiana Research Center, Shreveport, Louisiana, United States
|
| |
|
|
|
|
|
